Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: Olanzapine, a second-generation antipsychotic, is indicated by the U.S. Food and Drug Administration (FDA) for schizophrenia and bipolar I acute mania but has limited evidence for use in elderly patients with these conditions.1 Olanzapine was FDA-approved in December 2003 for maintenance monotherapy for bipolar disorder. Olanzapine at doses up to 20 mg is recommended to treat schizophrenia and acute mania.2 The package insert, however, recommends a lower dosage in geriatric patients, based upon studies of elderly with schizophrenia or dementia with psychotic symptoms, not those with acute mania.
From the Editors
Are you a healthcare provider?
Add your NPI to personalize your JCP experience.
This PDF is free for all visitors!